Our group has previously validated MER as a potential therapeutic target in NSCLC by demonstrating that shRNA-mediated MER knockdown results in decreased pro-oncogenic signaling, synergy with standard chemotherapeutic agents, increased induction of apoptosis, and decreased colony and tumor formation in long-term assays [13]. The gene discussed is MERTK; the disease is non-small cell lung carcinoma.